Stefan Abele, Ph.D.

Dr. Abele joined Pharvaris in 2023 with over 25 years of experience in the biopharmaceutical industry.

Previously, Dr. Abele served as Senior Vice President, Chemical Development and Commercial Manufacturing at Idorsia Pharmaceuticals from its inception in 2017. Dr. Abele’s teams led end-to-end Active Pharmaceutical Ingredients (API) and key cross-functional CMC activities from preclinical to late clinical phase and launch, and steered post-approval API life cycle activities. His teams were instrumental in reaching approval of and securing a resilient global API supply chain for QUVIVIQ (daridorexant) and PIVLAZ (clazosentan) in 2022 in key global markets, as well as supporting the submission of an NDA to the FDA in 2022 and a marketing authorization application to the EMA in 2023 for aprocitentan. Dr. Abele oversaw a globally diversified portfolio of suppliers covering raw materials, registered starting materials, and APIs.

From 2006 to 2017, Dr. Abele worked at Actelion Pharmaceuticals where he set up from scratch a fully integrated Chemistry Process R&D department with the mandate to scout for sustainable and scalable synthesis routes, produce first kg-amounts of API and develop 2^nd generation routes to cut the Cost of Goods of late-stage clinical candidates.

Prior to Actelion, Dr. Abele held positions of growing responsibility at Carbogen-Amcis, including Head Production, managing teams in R&D and GMP, manufacturing of more than 80 APIs for global pharma companies. Dr. Abele holds a Diploma in Chemistry from the University of Konstanz and a Ph.D. in Synthetic Organic Chemistry from the ETH Zurich in the laboratory of Prof. D. Seebach. His scientific track record and outreach is exemplified by more than 80 papers and patent applications. Dr. Abele serves on the Board of the DIAC (Division of Industrial and Applied Chemistry) of the Swiss Chemical Society and on the Editorial Board of the journal Organic Process Research and Development of the American Chemical Society.